{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"groups":[{"description":"Study Treatment:\n\n200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses.","id":"OG000","title":"Anti-PD-1 (MK-3475)"}],"paramType":"NUMBER","populationDescription":"32 patients were enrolled. 3 withdrew consent prior to treatment. Of the 29 treated, 26 were evaluable for response (subjects who received 2-9 doses of MK-3475 were evaluable). Of the 26, 23 completed end-of-treatment response evaluation and were included in primary endpoint analysis.","reportingStatus":"POSTED","timeFrame":"2 Years","title":"The Estimated Percentage of Patients Alive at 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of patients"}